Russia has announced a breakthrough in cancer research with the development of a new vaccine called Enteromyces, which has shown 100 percent effectiveness in its initial human trials. According to researchers, patients who received the vaccine experienced a significant reduction in tumors without any reported side effects. The vaccine uses mRNA technology, similar to that employed in Covid-19 vaccines, and is designed to train the immune system to identify and destroy cancer cells.
The clinical trial, conducted by the National Medical Research Radiological Center under the Russian Ministry of Health in collaboration with the Engelhardt Institute of Molecular Biology, involved 48 participants. Researchers reported not only tumor shrinkage but also a 60 to 80 percent slowdown in tumor growth. Enteromyces is currently being tested for use against colon cancer, but development is also underway for variants targeting aggressive brain cancers, specific skin cancers, and cancers of the eye.
The vaccine has been presented as a promising alternative to traditional treatments such as chemotherapy, which are often accompanied by severe side effects. By contrast, Enteromyces aims to provide a safer and more effective approach by harnessing the body’s own immune response. Scientists highlighted that the vaccine is the result of three years of preclinical research before moving into human trials.
The project has received strong backing from Russian authorities. Last year, Russia announced its intention to distribute a cancer vaccine free of charge, with rollouts expected to begin early next year once formal approvals are granted. President Vladimir Putin himself highlighted the progress in February last year, stating in a televised address that Russian scientists were nearing the final stages of developing a cancer vaccine that could soon be available to patients.
Alexander Gintsburg, director of the National Research Center for Epidemiology and Microbiology, had also previously confirmed the success of preclinical trials, further boosting optimism about the vaccine’s potential. Researchers and officials alike describe Enteromyces as a major step forward in the global fight against cancer, raising hopes that a more effective and less harmful treatment option may soon be within reach.
